Actively Recruiting
The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias
Led by Lin BioScience, Inc · Updated on 2026-03-27
90
Participants Needed
17
Research Sites
180 weeks
Total Duration
On this page
Sponsors
L
Lin BioScience, Inc
Lead Sponsor
L
Lin BioScience Pty Ltd
Collaborating Sponsor
AI-Summary
What this Trial Is About
The most common types of acute leukaemia are acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML). AML is a heterogenous clonal disorder of haemopoietic progenitor cells and the most common and severe malignant leukemia in adults and is responsible for the highest mortality from leukemia. ALL is a neoplasm characterized by the growth of malignant lymphoblasts of the B or T lineage, leading to an inhibition of proliferation of the normal blood cell lineages. The primary objectives of this study are investigating the safety, tolerability, and the MTD of LBS-007. The secondary objectives are to assess the efficacy and to determine the pharmacokinetics (PK) of LBS-007. The exploratory objective is to study and correlate the changes in surrogate biomarkers in response to treatment.
CONDITIONS
Official Title
The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female subjects greater than 18 years old, inclusive.
- Pathologically confirmed diagnoses of Relapsed or resistant AML or ALL.
- Patients who are ineligible for standard therapies that are anticipated to result in durable remission or cure, or who have no known therapy options of documented benefit.
- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.
You will not qualify if you...
- Concomitant chemotherapy, radiation therapy, or immunotherapy.
- Receiving any other investigational agents concurrently or within 30 days prior to screening.
- Patient has acute promyelocytic leukaemia or leukemia with active CNS involvement.
- History of another active malignancy with 2 years prior to study entry, basal cell skin cancer and previous carcinoma in treated curatively.
- Patient with mental deficits and/or psychiatric history that precludes them from giving informed consent or from following protocol.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 17 locations
1
Moffitt Cancer Center
Tampa, Florida, United States, 33612
Actively Recruiting
2
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Chicago, Illinois, United States, 60611
Not Yet Recruiting
3
The University of Kansas Hospital
Fairway, Kansas, United States, 66205
Actively Recruiting
4
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States, 21287
Actively Recruiting
5
UNC Hospitals, The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States, 27599
Actively Recruiting
6
Wollongong Private Hospital
Wollongong, New South Wales, Australia
Completed
7
Pindara Private Hospital
Benowa, Queensland, Australia
Completed
8
The Royal Adelaide Hospital
Adelaide, South Australia, Australia
Actively Recruiting
9
The Alfred Hospital
Melbourne, Victoria, Australia
Active, Not Recruiting
10
Hollywood Private Hospital
Nedlands, Washington, Australia
Withdrawn
11
Q Medical Conselling
Perth, Washington, Australia, 6009
Withdrawn
12
The First Affiliated Hospital of Xinxiang Medical University
Xinxiang, Henan, China, 453100
Actively Recruiting
13
Jining No.1 People's Hospital
Jining, Shandong, China, 272011
Actively Recruiting
14
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, China, 300020
Actively Recruiting
15
China Medical University Hospital
Taichung, Taiwan
Not Yet Recruiting
16
National Cheng Kung University Hospital
Tainan, Taiwan
Not Yet Recruiting
17
National Taiwan University Hospital
Taipei, Taiwan
Not Yet Recruiting
Research Team
L
Lin BioScience Clinical Operations
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here